RECURSION PHARMACEUT

RXRX
Delayed Quote. Delayed  - 05/18 04:00:00 pm
5.62USD -8.02%
Valuation
Fiscal Period: December 2021 2022
Capitalization1 2 8951 051
Enterprise Value (EV)1 2 379787
P/E ratio -11,5x-3,81x
Yield --
Capitalization / Revenue 284x24,0x
EV / Revenue 234x18,0x
EV / EBITDA -13,6x-3,21x
Price to Book 5,37x3,04x
Nbr of stocks (in thousands) 168 993172 007
Reference price (USD) 17,16,11
Announcement Date 03/23/2022-
Previous period Next period
1 USD in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2021 2022
Net sales1 10,243,7
EBITDA1 -174-245
Operating profit (EBIT)1 -183-238
Operating Margin -1 796%-543%
Pre-Tax Profit (EBT)1 -186-225
Net income1 -186-220
Net margin -1 832%-503%
EPS2 -1,49-1,60
Dividend per Share2 --
Announcement Date 03/23/2022-
Previous period Next period
1 USD in Million
2 USD
Estimates
Finances - Leverage
Fiscal Period: December 2021 2022
Net Debt1 --
Net Cash position1 516264
Leverage (Debt / EBITDA) 2,96x1,08x
Free Cash Flow1 -198-141
ROE (Net Profit / Equities) -111%-49,0%
Shareholders' equity1 168449
ROA (Net Profit / Asset) -41,0%-34,6%
Assets1 454636
Book Value Per Share2 3,192,01
Cash Flow per Share2 -1,27-0,29
Capex1 39,825,0
Capex / Sales 391%57,2%
Announcement Date 03/23/2022-
Previous period Next period
1 USD in Million
2 USD
Estimates
Financial Ratios
Size 2022e 2023e
Capitalization 1 051 M $ -
Enterprise Value (EV) 787 M $ 945 M $
Valuation 2022e 2023e
P/E ratio (Price / EPS) -3,81x -3,78x
Capitalization / Revenue 24,0x 18,2x
EV / Revenue 18,0x 13,6x
EV / EBITDA -3,21x -2,65x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 3,04x 3,08x
Profitability 2022e 2023e
Operating Margin (EBIT / Sales) -543% -492%
Operating Leverage (Delta EBIT / Delta Sales) - -
Net Margin (Net Profit / Revenue) -503% -422%
ROA (Net Profit / Asset) -34,6% -42,2%
ROE (Net Profit / Equities) -49,0% -66,7%
Rate of Dividend - -
Balance Sheet Analysis 2022e 2023e
CAPEX / Sales   57,2% 47,5%
Cash Flow / CA -113% -441%
Capital Intensity (Assets / Revenue) 14,5x 10,0x
Financial Leverage (Net Debt / EBITDA) - -
EPS & Dividend